DiaMedica rises after FDA feedback clears path for preeclampsia drug study
16/06/2026 13:53
BUZZ-DiaMedica rises after FDA feedback clears path for preeclampsia drug study ** Shares of biotech firm DiaMedica Therapeutics DMAC.O rise 5.7% to $5.95 premarket
** Co says FDA feedback allows prior rat study of dm199, a lab-made protein therapy, to support U.S. human trial application for preeclampsia if drug exposure is confirmed
** Preeclampsia is a serious pregnancy condition marked by high blood pressure that can harm mother and baby
** DMAC says it will run a new rat study to measure drug levels and the drug's activity to meet the FDA's request
** Says dm199 is also being tested for stroke and fetal growth problems
** It plans to start preeclampsia studies in Canada and UK later this year
** As of last close, stock down ~29% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program